## Domenica Ronchetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4705308/publications.pdf

Version: 2024-02-01

48 papers

1,895 citations

257450 24 h-index 42 g-index

48 all docs

48 docs citations

times ranked

48

2795 citing authors

#	Article	IF	CITATIONS
1	A Novel Chromosomal Translocation t(4; 14)(p16.3; q32) in Multiple Myeloma Involves the Fibroblast Growth-Factor Receptor 3 Gene. Blood, 1997, 90, 4062-4070.	1.4	201
2	An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Medical Genomics, 2008, 1, 37.	1.5	104
3	Differential repetitive DNA methylation in multiple myeloma molecular subgroups. Carcinogenesis, 2009, 30, 1330-1335.	2.8	99
4	Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene, 2001, 20, 3553-3562.	5.9	98
5	Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma. Clinical Cancer Research, 2009, 15, 5369-5378.	7.0	91
6	A p53â€Dependent Tumor Suppressor Network Is Induced by Selective miRâ€125aâ€5p Inhibition in Multiple Myeloma Cells. Journal of Cellular Physiology, 2014, 229, 2106-2116.	4.1	86
7	Molecular Analysis of 11q13 Breakpoints in Multiple Myeloma. Blood, 1999, 93, 1330-1337.	1.4	80
8	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia, 2020, 34, 234-244.	7.2	80
9	Distinct IncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma. Oncotarget, 2016, 7, 14814-14830.	1.8	79
10	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. BMC Medical Genomics, 2013, 6, 27.	1.5	73
11	The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. Blood Cancer Journal, 2012, 2, e96-e96.	6.2	70
12	Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease. Genes Chromosomes and Cancer, 2007, 46, 226-238.	2.8	62
13	Integrative highâ€resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes and Cancer, 2009, 48, 521-531.	2.8	60
14	Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. Oncotarget, 2017, 8, 106527-106537.	1.8	60
15	Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosomes and Cancer, 2005, 42, 117-127.	2.8	49
16	lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. Blood Cancer Journal, 2016, 6, e468-e468.	6.2	47
17	Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. , 1998, 79, 263-268.		46
18	Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia, 2007, 21, 1113-1116.	7.2	45

#	Article	IF	CITATIONS
19	p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity. Laboratory Investigation, 2002, 82, 1327-1334.	3.7	40
20	<i>IL21R</i> expressing CD14 <sup>+</sup> CD16 <sup>+</sup> monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica, 2017, 102, 773-784.	3.5	36
21	Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers, 2019, 11, 236.	3.7	35
22	A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma. Scientific Reports, 2018, 8, 6557.	3.3	34
23	Identification of a Novel Gene,PSD,Adjacent toNFKB2/lyt-10,Which Contains Sec7 and Pleckstrin-Homology Domains. Genomics, 1997, 46, 251-259.	2.9	27
24	Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. Haematologica, 2019, 104, e72-e76.	3.5	27
25	LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?. Non-coding RNA, 2020, 6, 26.	2.6	27
26	Long non-coding RNAs in B-cell malignancies: a comprehensive overview. Oncotarget, 2017, 8, 60605-60623.	1.8	25
27	Reverse transcriptase/polymerase chain reaction followâ€up and minimal residual disease detection in t(1;19)â€positive acute lymphoblastic leukaemia. British Journal of Haematology, 1996, 92, 653-658.	2.5	24
28	Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma. British Journal of Haematology, 2005, 131, 214-218.	2.5	24
29	Long Non-Coding RNAs in Multiple Myeloma. Genes, 2018, 9, 69.	2.4	22
30	In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma. Genes, 2016, 7, 107.	2.4	17
31	Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities. Cancers, 2021, 13, 3213.	3.7	16
32	Repetitive DNA Hypomethylation in Multiple Myeloma. Blood, 2008, 112, 2703-2703.	1.4	16
33	Association Between p53 Gene Mutations and Tobacco and Alcohol Exposure in Laryngeal Squamous Cell Carcinoma. JAMA Otolaryngology, 2004, 130, 303.	1.2	15
34	DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. Haematologica, 2022, 107, 921-932.	3.5	14
35	NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome. Non-coding RNA, 2020, 6, 11.	2.6	11
36	Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2014, 53, 264-273.	2.8	10

#	Article	IF	CITATIONS
37	Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting. Biochemical Pharmacology, 2009, 78, 1139-1147.	4.4	9
38	Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma. Hematological Oncology, 2007, 25, 6-10.	1.7	8
39	Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with $t(11;14)$ Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity. Cancers, 2021, 13, 4898.	3.7	8
40	Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma. Cancers, 2020, 12, 782.	3.7	6
41	In Vitro Silencing of IncRNAs Using LNA GapmeRs. Methods in Molecular Biology, 2021, 2348, 157-166.	0.9	5
42	Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs. Journal of Clinical Medicine, 2021, 10, 1295.	2.4	5
43	Clinical relevance of p53 and bclâ€2 protein overâ€expression in laryngeal squamousâ€cell carcinoma. International Journal of Cancer, 1998, 79, 263-268.	5.1	2
44	Lack of Bcl10 gene mutations in laryngeal squamous cell carcinoma. Journal of Laryngology and Otology, 2002, 116, 610-612.	0.8	1
45	Bioinformatics Pipeline to Analyze IncRNA Arrays. Methods in Molecular Biology, 2021, 2348, 45-53.	0.9	1
46	Molecular and Transcriptional Characterization of the Novel $17p11.2$ - $p12$ Chromosome Amplification in Multiple Myeloma Blood, 2007, $110$ , 2486-2486.	1.4	0
47	Genome-Wide Analysis of DNA Copy Number in Multiple Myeloma Using High-Density SNP Arrays Reveals Clustering Patterns with Distinct Transcriptional Profiles Blood, 2007, 110, 2482-2482.	1.4	0
48	Dissecting the Biological Relevance and Clinical Impact of IncRNA MIAT in Multiple Myeloma. Cancers, 2021, 13, 5518.	3.7	0